#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
preLekára.sk / Journals / Epidemiology, Microbiology, Immunology / 2024 - 1

Infection of respiratory syncytial viruses (RSV) in the Czech Republic – analysis of hospitalizations and deaths in 2017–2022

Česká verzia

Authors: P. Pazdiora 1 ;  O. Šanca 2 ;  L. Dušek 3
Authors place of work: Ústav epidemiologie, Lékařská fakulta v Plzni, Univerzita Karlova, Plzeň 1;  Ústav zdravotnických informací a statistiky České republiky, Praha 2;  Institut biostatistiky a analýz, Lékařská fakulta, Masarykova univerzita, Brno 3
Published in the journal: Epidemiol. Mikrobiol. Imunol. 73, 2024, č. 1, s. 21-29
Category: Original Papers
doi: https://doi.org/10.61568/emi/11-6254/20240123/136239

Summary

Objectives: Given the lack of data on the seriousness of respiratory syncytial virus (RSV) infections in the Czech Republic, an analysis was made of available data on hospitalizations and the hospitalization risk was estimated by age group.

Methods: Data from the National Registry of Reimbursed Health Services and the National Registry of Hospitalizations were used for the analyses. Hospitalizations and deaths due to RSV infection (diagnoses J12.1, J20.5, J21.0) from 2017-2022 were analyzed by age group.

Results: Over the six-year period, there were 6,138 hospitalizations with the above diagnoses, ranging between years from 307 to 2,162. The estimated overall hospitalization risk per 100,000 population and year for diagnoses J12.1, J20.5, and J21.0 was 9.64, varying between 2.87 (2020) and 20.56 (2021). Age-group analysis showed the highest risk for children under 6 months of age (891.6/100,000 population and year) and the lowest for 20-34-year-olds (0.1/100,000 population and year). Children under 1 year of age accounted for 63.1% of hospitalizations with the above diagnoses. For patients 65 years and older, the annual hospitalization rates varied between 3.3–15.3%. The most frequent cause of RSV-associated hospitalizations was bronchitis, diagnosed in 55.4% of patients. Among those hospitalized with diagnoses J12.1, J20.5, and J21.0, 38 deaths were reported, representing a case fatality rate of 0.62%. The highest case fatality rate (6.5%) was observed in the age group 35–49 years.

Conclusions: RSV-associated hospitalizations have been reported in all age groups in the Czech Republic. The highest RSV-associated hospitalization risk in 2017–2022 was estimated among children under 6 months of age. Passive surveillance using the available registries could currently provide the basis for measures specifically tailored to the youngest age categories. Data on the hospitalization of adults, particularly senior citizens, must be improved and complemented with active surveillance.

Keywords:

hospitalization – Bronchitis – Bronchiolitis – pneumonia – respiratory syncytial viruses – deaths

Zdroje
  1. Arriola CS, Kim L, Langley G, et al. Estimated Burden of Community-Onset Respiratory SyncytialVirus-Associated Hospitalizations Among Children Aged <2 Years in the United States, 2014–15. J Pediatric Infect Dis Soc, 2020;9(5):587–595.
  2. Bardsley M, Morbey RA, Hughes HE, et al. Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study. Lancet Infect Dis, 2023;23(1):56–66.
  3. Beran J, Ramirez Villaescusa A, Devadiga R, et al. Respiratory syncytial virus acute respiratory infections in ≥ 65-year-old adults in long-term care facilities in the Czech Republic. Cent Eur J Public Health, 2021;29(3):167–176.
  4. Colosia AD, Yang J, Hillson E, et al. The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A systematic review. PLoS One, 2017;12(8):e0182321.
  5. Cong B, Dighero I, Zhang T, et al. Understanding the age spectrum of respiratory syncytial virus associated hospitalisation and mortality burden based on statistical modelling methods: a systematic analysis. BMC Med, 2023;21(1):224.
  6. Del Riccio M, Spreeuwenberg P, Osei-Yeboah R, et al. RESCEU investigators. Defining the Burden of Disease of RSV in the European Union: estimates of RSV-associated hospitalisations in children under 5 years of age. A systematic review and modelling study. J Infect Dis, 2023;29:jiad188.
  7. Duan Y, Jiang M, Huang Q, et al. Incidence, hospitalization, and mortality in children aged 5 years and younger with respiratory syncytial virus-related diseases: A systematic review and meta-analysis. Influenza Other Respir Viruses, 2023;17(5):e13145.
  8. ECDC: Intensified circulation of respiratory syncytial virus (RSV) and associated hospital burden in the EU/EEA, Risk assessment, 12 Dec 2022.
  9. Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med, 2005;352(17):1749–1759.
  10. Falsey AR, Walsh EE. Respiratory syncytial virus infection in elderly adults. Drugs Aging, 2005;22(7):577–587.
  11. Falsey AR, McElhaney JE, Beran J, et al. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. J Infect Dis, 2014;209(12):1873–1881.
  12. Gil-Prieto R, Gonzalez-Escalada A, Marín-García P, et al. Respiratory syncytial virus bronchiolitis in children up to 5 years of age in Spain: epidemiology and comorbidities: an observational study. Medicine (Baltimore), 2015;94(21):e831.
  13. Hall CB, Long CE, Schnabel KC. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis, 2001;33(6):792–796.
  14. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med, 2009;360(6):588–598.
  15. Hansen CL, Chaves SS, Demont C, et al. Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999– 2018. JAMA Network Open, 2022;5(2):e220527.
  16. Hubáček P, Smíšková D. Infekce vyvolané respiračními syncytiálními viry – epidemiologie, klinický obraz, diagnostika, možnosti prevence a léčby. Ces-slov Pediat, 2023; 78(Suppl 1):S13–19.
  17. Chuang YC, Lin KP, Wang LA, et al. The Impact of the COVID-19 Pandemic on Respiratory Syncytial Virus Infection: A Narrative Review. Infect Drug Resist, 2023;16:661–675.
  18. Jepsen MT, Trebbien R, Emborg HD, et al. Incidence and seasonality of respiratory syncytial virus hospitalisations in young children in Denmark, 2010 to 2015. Euro Surveil, 2018;23(3):pii=17– 00163.
  19. Johannesen CK, van Wijhe M, Tong S et al. RESCEU Investigators. Age-Specific Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series Analysis. J Infect Dis, 2022;226(Suppl 1):S29–S37.
  20. Lee N, Walsh EE, Sander I, et al. Delayed Diagnosis of Respiratory Syncytial Virus Infections in Hospitalized Adults: Individual Patient Data, Record Review Analysis and Physician Survey in the United States. J Infect Dis, 2019;220(6):969–979.
  21. Li Y, Wang X, Blau DM, et al. RESCEU investigators. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet, 2022;399(10340):2047–2064.
  22. Li Y, Wang X, Broberg EK, et al. European RSV Surveillance Network. Seasonality of respiratory syncytial virus and its association with meteorological factors in 13 European countries, week 40 2010 to week 39 2019. Euro Surveill, 2022;27(16):2100619.
  23. McLaughlin JM, Khan F, Begier E, et al. Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis. Open Forum Infect Dis, 2022;9(7):ofac300.
  24. McLaughlin JM, Khan F, Schmitt HJ, et al. Respiratory Syncytial Virus-Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis. J Infect Dis, 2022;225(6):1100–1111.
  25. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet, 2010;375:1545–1555.
  26. Nguyen-Van-Tam JS, O’Leary M, Martin ET, et al. Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries. Eur Respir Rev, 2022;31(166):220105.
  27. Nowalk MP, D’Agostino H, Dauer K, et al. Estimating the burden of adult hospitalized RSV infection including special populations. Vaccine, 2022;40(31):4121–4127.
  28. Osei-Yeboah R, Spreeuwenberg P, Del Riccio M, et al. RESCEU investigators. Estimation of the number of RSV-associated hospitalisations in adults in the European Union. J Infect Dis, 2023:jiad189.
  29. PATH. Advancing Maternal Immunization. Advancing RSV Maternal Immunization: A Gap Analysis Report. July 2018. Accessed October 28, 2021. Dostupné na www: https://www.path.org/ resources/advancing-rsv-maternal-immunization-gap-analysis-report/
  30. Principi N, Autore G, Ramundo G, et al. Epidemiology of Respiratory Infections during the COVID-19 Pandemic. Viruses, 2023;15(5):1160.
  31. Pruccoli G, Castagno E, Raffaldi I, et al. The Importance of RSV Epidemiological Surveillance: A Multicenter Observational Study of RSV Infection during the COVID-19 Pandemic. Viruses, 2023;15(2):280.
  32. Prymula R, Pazdiora P, Dušek L. Infekce RSV v ČR – analýza hospitalizací v letech 2017–2021. Vakcinologie, 17;2023(1):6–14.
  33. Raes M, Daelemans S, Cornette L, et al. The burden and surveillance of RSV disease in young children in Belgium-expert opinion. Eur J Pediatr, 2023;182(1):451–460.
  34. Rha B, Curns AT, Lively JY, et al. Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015–2016. Pediatrics, 2020;146(1):e20193611.
  35. Rozenbaum MH, Begier E, Kurosky SK, et al. Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of Current Data. Infect Dis Ther, 2023;12(6):1487–1504.
  36. Rozenbaum MH, Judy J, Tran D, et al. Low Levels of RSV Testing Among Adults Hospitalized for Lower Respiratory Tract Infection in the United States. Infect Dis Ther, 2023;12(2):677–685.
  37. Savic M, Penders Y, Shi T, et al. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis. Influenza Other Respir Viruses, 2023;17(1):e13031.
  38. Shi T, McAllister DA, O’Brien KL, et al. RSV Global Epidemiology Network. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet, 2017;390(10098):946–958. 
  39. Shi T, Denouel A, Tietjen AK, et al. RESCEU Investigators. Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis. J Infect Dis, 2020;222(Suppl 7):S577–S583.
  40. Staadegaard L, Caini S, Wangchuk S, et al. The Global Epidemiology of RSV in Community and Hospitalized Care: Findings From 15 Countries. Open Forum Infect Dis, 2021;8(7):ofab159.
  41. Straňák Z. Doporučení České neonatologické společnosti ČLS JEP a Společnosti dětské pneumologie pro imunoprofylaxi závažných forem RSV infekce. Čes-Slov Neonat, 2023; 29(1):77–78.
  42. SZÚ, Výskyt akutních respiračních infekcí a chřipky v ČR. Dostupné na www: https://szu.cz/publikace-szu/data/akutni-respiracni-infekce-chripka/.
  43. Tabatabai J, Ihling CM, Rehbein RM, et al. Molecular epidemiology of respiratory syncytial virus in hospitalised children in Heidelberg, Southern Germany, 2014–2017. Infect Genet Evol, 2022;98:105209.
  44. Teirlinck AC, Broberg EK, Stuwitz Berg A, et al. Recommendations for respiratory syncytial virus surveillance at the national level. Eur Respir J, 2021;58(3):2003766.
  45. ÚZIS ČR. Národní registr hospitalizovaných. Závazné pokyny. Verze NZIS 020_20140701. 26 s.
  46. Welliver RC Sr, Checchia PA, Bauman JH, et al. Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr Med Res Opin, 2010;26(9):2175– 2181.
  47. Wildenbeest JG, Billard MN, Zuurbier RP, et al. RESCEU Investigators. The burden of respiratory syncytial virus in healthy termborn infants in Europe: a prospective birth cohort study. Lancet Respir Med, 2023;11(4):341–353.

Poděkování

Poděkování za technickou spolupráci patří Bc. Š. Merhoutové z Ústavu epidemiologie LF v Plzni.

Práce byla podpořena v rámci programu Cooperatio.

Do redakce došlo dne 17. 8. 2023.

Adresa pro korespondenci:
prof. MUDr. Petr Pazdiora, CSc.
Ústav epidemiologie LF v Plzni, UK
Edvarda Beneše 13
301 00 Plzeň
e-mail: pazdiora@fnplzen.cz

Štítky
Hygiene and epidemiology Medical virology Clinical microbiology
Článek Analysis of enterobiasis in the Czech Republic in 2018–2022
Článek Issues of risky behaviours in university students
Článek Posibilities for use of whole genome sequencing (WGS) for the analysis of Streptococcus pneumoniae isolates
Článek Human papillomavirus infection (HPV) and pregnancy
Článek Lessons from the COVID-19 pandemic.
Článek News
Článek Personal news
Článek Instruction to authors and reviewers
Článok vyšiel v časopise

Epidemiology, Microbiology, Immunology

Číslo 1
2024 Číslo 1
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#